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Abstract Article Info 
Introduction: Epstein Barr Virus (EBV) infection is responsible for nasopharyngeal carcinoma (NPC). LMP1 
as the product of express gene by EBV latent infection is responsible in inducing Matrix Metalloproteinase–9 
(MMP-9) and Cyclooxygenase–2 (COX-2). The two factors are associate with the metastasis of cancer and were 
thought to be a prognostic factor in nasopharyngeal carcinoma patients.   
Objective: The aim of this study was to analyze the overexpression of MMP-9 and COX-2 in NPC patients and 
the combination of those two with the clinical staging of NPC which lead to an evidence of those two in NPC. 
This study also needed to reveal the association of MMP-9 expression in response of COX-2 expression.   
Methods: This study was a cross sectional design study with statistical analytic approach. Samples was paraffin 
blocks which taken from the patients diagnosed with NPC with non-probability consecutive sampling method 
and underwent immunohistochemistry staining. Fisher’s exact test and Chi-square test was conducted to analyze 
the data, significant if P<0.05. 
Results: From the total 98 samples, we found the highest overexpression of MMP-9, COX-2, and both of them 
in nasopharyngeal carcinoma were in WHO Type II (80.8%; 78.8%; 78.6%), T3 (35.9%; 40.0%; 38.6%), N3 
(53.8%; 53.8%; 60.0%), M1 (69.2%; 67.5%; 75.7%), and stage IV NPC (69.2%; 67.5%; 75.7%), respectively. 
There were significant association of primary tumor size, lymph node enlargement, the presence of distant 
metastasis, and clinical staging in the overexpression of MMP-9, COX-2, and both of them, but not 
histopathological type. There was association between MMP-9 with COX-2 in nasopharyngeal carcinoma 
patients.  
Conclusion: Overexpression of MMP-9, COX-2, and both of them occurs correspondence with increase clinical 
staging. COX-2 is associate with MMP-9 and those two may be used as prognostic biomarker.  
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Nasopharyngeal carcinoma (NPC) is a unique cancer with clearly 
geographic distribution. It is squamous cell cancer arising from the epithelial 
cells of the nasopharynx which is located behind nasal cavity. The most 
common site of origin for this disease is the fossa Rosenmüller [1]. It is more 
common in Southeast Asia and artic region such as North America and 
Greenland. The ethnic region which more common suffered nasopharyngeal 
carcinoma are southern Chinese, Amazigh- and Arabic-speaking North 
Africans and Inuit. Nasopharyngeal carcinoma is common in male than 
female with comparison 2-3:1. According to GLOBOCAN 2012, incidence 
of nasopharyngeal carcinoma in Indonesia were 3/100.000 in male and 
3.0/100.000 in female based on Age Standardized Rate (ASR) [2, 3]. 
Nasopharyngeal carcinoma arise from complex relationship of genetic, 
environment, and Epstein Barr Virus (EBV) infection. There were thought 
that chromosomal abnormalities have been found as one of the causes of this 
disease. The abnormalities that have found were gains at chromosome 1q, 
3q, 8q, 12p, 12q and losses at 3p, 9p, 11q, 14q and 16q. That chromosomes 
were suggested as locations of oncogenes and tumor suppressor genes. [2, 
4] Another genetic influence on nasopharyngeal carcinoma development 
were polymorphism of Human Leucocyte Antigen (HLA), allele p53, and 
enzyme for carcinogen metabolism and detoxification [5]. Consumption of 
preserved salted fish was known had association of increase the risk of 
nasopharyngeal carcinoma. Smoking also was thought to be risk factor for 
the disease, mainly in differentiated squamous cell carcinoma [2]. 
Involvement of EBV infection in the pathogenesis of nasopharyngeal 
carcinoma was based from the evidence that there was elevation of antibody 
against EBV in the patients and the presence of EBV DNA and RNA in the 
tumor cells. EBV latent infection express several genes responsible for 
development nasopharyngeal carcinoma including Latent Membrane 
Protein 1 (LMP1), LMP2, Epstein Barr nuclear Antigen (EBNA-1), and 
Epstein Barr Virus-encoded small RNAs (EBER) [2, 6].  
LMP1 was suggested to increase the transcription of Matrix 
Metalloproteinases-9 (MMP-9) which responsible for the invasion of tumor cells 
to extracellular matrix. The mechanism of induction was associated by signaling 
pathway including NF-κB, AP-1, ERK-MPK, and ets-1 [7]. This enzyme has the 
role for metastasis in nasopharyngeal carcinoma. [6] It was found that MMP-9 
might be a prognostic marker for nasopharyngeal carcinoma patients which 
showed the increase of the disease progression [8]. 
However, it was also suggested that LMP1 also induce Cyclooxygenase-2 
(COX-2) upregulation, with others factor including Vascular Epithelial Growth 
Factor (VEGF), Epidermal Growth Factor Receptor (EGFR) and others 
biomarker enhance proliferation [9]. Upregulation of COX-2 is common in 
cancer. It produces prostaglandin E2 (PGE2) which is responsible in cancer cells 
protection against apoptosis and induce invasiveness, angiogenesis, proliferation, 
and metastasis of the cancer cells [10]. It also suggested as a prognostic marker 
for the nasopharyngeal carcinoma patients [11]. 
Relation of MMP-9 and COX-2 was remain unclear in nasopharyngeal 
carcinoma patients.  The overexpression of those two along in several cancers 
were found in several studies, but the actual association between MMP-9 and 
COX-2 is relatively rare in the published study [12-14]. This study was 
conducted to analyze the overexpression of those two in nasopharyngeal 
carcinoma patients and the relation with clinical staging. Further, it may provide 
basis study using MMP-9 and COX-2 as prognostic biomarker.  
2. MATERIALS AND METHODS 
2.1  Patients and Samples 
The study had 98 total samples which were taken from biopsy specimens 
stored as paraffin blocks, from patients who were confirmed as NPC at Adam 
Malik Hospital Medan in 2017. The histopathological diagnosed was done in 
the Department of Anatomic Pathology of the Faculty of Medicine Universitas 
Sumatera Utara as well as immunohistochemistry staining for the evaluation 
of MMP-9 and COX-2 expression. 







Samples were taken in non-probability consecutive sampling method. 
The patients had no other malignancies and agreed upon the informed 
consent to be participants of the study. Besides, they had not received any 
form of treatment such as radiotherapy, chemotherapy, or both.  
Expression of MMP-9, expression of COX-2, primary tumor size (T), 
lymph node enlargement (N), and clinical staging were established as the 
variable of the study. Evaluation of primary tumor size (T1-T4) and lymph 
node enlargement (N0-N3) were done using imaging of computed 
tomography (CT) scan with contrast based on AJCC 2010. Staging of the 
cancer (Stage I-IV) was determined based on the American Joint Committee 
on Cancer (AJCC) staging system 2010. The histopathological type of 
cancer was determined based on WHO classification. Overexpression of 
MMP-9 and COX-2 were evaluated by immunohistochemistry staining 
based on immunoreactive score (IRS) . IRS was calculated by multiplication 
of staining intensity (0= none; 1=weak; 2=moderate; and 3=strong staining) 
and the percentage of positively-stained cells (0=no stained cells; 1=1–10% 
stained cells; 2=11–50% stained cells; 3=51–80% stained cells and 4=81–
100% stained cells). It called overexpression of COX-2 and MMP-9 if IRS 
was more than 3 [15, 16]. The study has been approved by the Health 
Research Ethical Committee, Medical Faculty of Universitas Sumatera 
Utara/Adam Malik General Hospital and the methods did not contradicted 
with the Declaration of Helsinki. 
2.2  Immunohistochemistry Staining 
Paraffin embedded blocks specimens were cut into sections and stain 
with hematoxylin–eosin to determine the histopathological type of the 
cancer. The specimens then were deparaffinized and followed by antigen 
retrieval by set up preheat in 650C, and running time in 980C for 15 minutes. 
The specimens were incubated with the primary antibody using human 
MMP-9 and COX-2 antibody.  The tissue were evaluated independently for 
the expression of MMP-9 and COX-2 under fluorescent microscope by three 
pathologist which blind with the clinical parameters of the patients.  
 
 
Picture 1. Cytoplasmic expression of MMP-9 in non-keratinizing 
squamous cell nasopharyngeal carcinoma (x 400) 
 
Picture 2. Cytoplasmic expression of COX-2 in non-keratinizing 
squamous cell nasopharyngeal carcinoma (x 400) 
2.3  Statistical Analysis 
Analysis of all the data were gathered in the study was using the 
Statistical Package for Social Sciences (SPSSTM) computer program. 
Fisher’s exact test was used to analyze the primary tumor, lymph node 
metastasis, and clinical staging and chi-square test was used to evaluate the 
correlation between MMP-9 with COX-2 in nasopharyngeal carcinoma 
patients. The correlation is found if P-Value <0.05. 
3. RESULTS 
The total patients met inclusion criteria were 98 nasopharyngeal 
carcinoma patients. Table 1 showed the demographic data from the 
samples based on distribution of age, sex, and WHO classification. 
According to the gender, there were 73 males (74.5%) and 25 females 
(25.5%). However, based on the age, the patients were common in the age 
of 41–60 year old, which were 56 people (57.1%) and the second was 
patients with 21–40 years of age with 22 people (22.4%), followed by >60 
years old with 15 people (15.3%). The age group of ≤20 years old was the 
last group with 5 people (5.1%).  
It shown that from 98 samples, the most common histopathological type 
in nasopharyngeal carcinoma patients based on WHO classification in the 
study were 79 samples (80.6%) categorized as non-keratinizing squamous 
cell carcinoma (WHO Type II), followed by 12 samples (12.2%) with 
undifferentiated carcinoma ((WHO Type III), and keratinizing squamous 
cell carcinoma (WHO Type I), with 7 samples (7.1%). 
Table 1. Demographic Distribution Based on Age, Sex, and WHO 
classification 
                          Characteristic n        % 
Age (years)    
≤20    5 5.1 
21–40  22 22.4 
41–60  56 57.1 
 60  15 15.3 
Sex    
Male  73 74.5 
Female  25 25.5 
WHO classification 
WHO Type I 
WHO Type II 








  7.1 
         80.6 
         12.2 
    
MMP-9 overexpression was positively found in 78 samples (79.6%) 
and negative overexpression of MMP-9 were found in 20 samples (20.4%) 
of nasopharyngeal carcinoma patients. Based on histopathological type, 
overexpression of MMP-9 was the highest in WHO Type II with 63 samples 
(80.8%). The second highest was WHO Type III with 8 samples (10.3%), 
and then followed by WHO Type I with 7 samples (9.0%). Fisher Exact test 
showed there was no significant association of histopathological type with 
the occurrence of MMP-9 overexpression (P= 0.275).  
Based on primary tumor size, the overexpression of MMP-9 was most 
found in T3 with 28 samples (35.9%). The second was T4 with 22 samples 
(28.2%) and followed by T2 with 19 samples (24.4%) and the last was T1 
with just 9 samples (11.5%).  
The highest number for occurrence of MMP-9 overexpression was 
found in N3 nasopharyngeal carcinoma patients with 42 samples (53.8%) 
based on lymph node enlargement. Then, it followed by N2 and N1 with 17 
and 10 samples (21.8% and 12.8%), respectively. And at least was N0 
nasopharyngeal carcinoma patients with 9 samples (11.5%). The 
overexpression of MMP-9 was highest in the presence of distant metastasis 
with 54 samples (69.2%) and lowest in the absence of distant metastasis 
with 24 samples (30.8%). 
According to the clinical staging, the overexpression of MMP-9 was 
found highest in stage IV with 54 samples (69.2%), followed by stage III 
with 16 samples (20.5%). Stage I and stage II was accounted for both 4 
samples (5.1%). The incidence of the overexpression were increased as the 
increase of staging. There was significant association of MMP-9 
overexpression with primary tumor size, lymph node enlargement, and 
clinical staging (P< 0.001) using Fisher’s exact test.  
Overexpression of COX-2 was found in 80 samples (81.6%) and was 
not found in 18 samples (18.4%).  It shown that the positive overexpression 
of COX-2 was mostly occur than its negative overexpression. Based on the 
histopathological type, WHO Type II was found as the common of COX-2 







overexpression occurrence with 63 samples (78.8%).   The second was 
WHO Type III with 10 samples (12.5%), and followed by WHO type I with 
7 samples (8.8%).  The overexpression of COX-2 was not associate 
significantly with the histopathological type (P=0.614). 
Table 2. Overexpression MMP-9 and COX-2 according to clinical characteristics of NPC 
Characteristic 
MMP-9 and COX-2 Overexpression 
Combination 
of  MMP-9 
and COX-2 
                P-Value                   MMP-9            P-value           COX-2      P-Value    Negative       P-Value 
WHO classification  0.278*  0.275*  0.614*  
 
0.339* 
 WHO  Type I 7 (10.0%)     7   (9.0%)     7   (8.8%)  1   (10.0%)  
 WHO Type II 55 (78.6%)    63 (80.8%)  63 (78.8%)  7   (70.0%)  
 WHO Type III 8 (11.4%)  8 (10.3%)  10 (12.5%)  2   (20.0%)  
Primary tumor size  <0.001*  <0.001*  <0.001*  
 
0.001* 
 T1 4 (5.7%)        9 (11.5%)  5   (6.3%)  6   (60.0%)  
 T2 18 (25.7%)        19 (24.4%)  21 (26.3%)  3   (30.0%)  
 T3 27 (38.6%)        28 (35.9%)  32 (40.0%)  1   (10.0%)  
 T4 21 (30.0%)  22 (28.2%)  22 (27.5%)  0     (0.0%)  




 N0 6   (8.6%)  9 (11.5%)    8 (10.0%)  5   (50.0%)  
 N1 9 (12.9%)          10 (12.8%)  14 (17.5%)  1   (10.0%)  
 N2 13 (18.6%)          17 (21.8%)  15 (18.8%)  4   (40.0%)  
 N3 42 (60.0%)          42 (53.8%)  43 (55.8%)  0     (0.0%)  
Distant Metastasis 
               M0 

















  <0.001* 
26 (32.5%) 















 I 1   (1.4%)     4   (5.1%)  2   (2.5%)  5   (50.0%)  
 II 3   (4.3%)  4   (5.1%)  6   (7.5%)  2   (20.0%)  
 III 13 (18.6%)  16 (20.5%)  18 (22.5%)  3   (30.0%)  
 IV 53 (75.7%)  54 (69.2%)  54 (67.5%)  0     (0.0%)  
*fisher's exact 
 
The primary tumor size which was the most common for COX-2 
overexpression was T3 with 32 samples (40.0%). Primary tumor size of T4 
and T2 were slightly similar with 22 and 21 samples (27.5% and 26.3%), 
respectively. The lowest occurrence of COX-2 overexpression was T1 with 
5 samples (6.3%).  
Nasopharyngeal carcinoma patients with lymph node enlargement N3 
was the most common for COX-2 overexpression with 43 samples (55.8%) 
and followed by N2 and N1 with 15 samples (18.8%) and 14 samples 
(17.5%), respectively. The overexpression of COX-2 in N0 was the lowest 
with 8 samples (10.0%). COX-2 overexpression was found highest in the 
presence of distant metastasis with 54 samples (67.5%) and followed by the 
absence of distant metastasis with 26 samples (32.5%).  
Overexpression of COX-2 was found the highest in stage IV 
nasopharyngeal carcinoma patients with 54 samples (67.5%). The second 
was stage III with 18 samples (22.5%), followed by stage II and stage I with 
6 samples (7.5%) and 2 samples (2.5%), respectively. The overexpression 
of COX-2 was concordance with the increase of stage in nasopharyngeal 
carcinoma patients. Primary tumor size, lymph node enlargement, and 
clinical staging were significantly associate with the overexpression of 
COX-2 in nasopharyngeal carcinoma patients (P< 0.001). 
Table 2 showed the distribution of expression both of MMP-9 and 
COX-2 according to histopathological type, primary tumor size, lymph node 
enlargement, and clinical staging. WHO Type II was the highest in 
occurrence of both MMP-9 and COX-2 overexpression with 55 samples 
(78.6%) based on histopathological type. It then followed by WHO Type I 
and WHO Type III with 7 samples (10.0%) and 8 samples (11.4%), 
respectively. There was no significantly association of histopathological 
type with the overexpression of both MMP-9 and COX-2 (P= 0.278).  
 According to primary tumor size, T3 was the most common in 
the overexpression of MMP-9 and COX-2 combination with 27 samples 
(38.6%) and then followed by T4 with 21 samples (30.0%) and T2 with 18 
samples (25.7%). The lowest occurrence for the overexpression both of 
those two was in T1 with 4 samples (5.7%).  
 Lymph node enlargement N3 was the highest occurrence of both 
MMP-9 and COX-2 overexpression with 42 samples (60.0%) and followed 
by N2 with 13 samples (18.6%). Those two then were followed by N1 and 
N0 with 9 samples (12.9%) and 6 samples (8.6%), respectively. Based on 
the metastasis, the overexpression of both MMP-9 and COX-2 was found 
highest in the presence of distant metastasis with 53 samples (75.7%) 
compared with the absence of distant metastasis with 17 samples (24.3%). 




   Positive Negative 
MMP-9 Overexpression 
Positive  70 (87.5%)   8 (44.4%)         
<0.001** Negative  10 (12.5%) 10 (55.6%) 
**Chi-square test 
 
Overexpression of both MMP-9 and COX-2 were most common in 
stage IV nasopharyngeal carcinoma patients with 53 samples (75.7%) and 
followed by stage III with 13 samples (18.6%). Lower overexpression of 
those two were found in stage II and I with 3 samples (4.3%) and 1 samples 
(1.4%), respectively. There were significant association of primary tumor 
size, lymph node enlargement, and clinical staging with the overexpression 
of both MMP-9 and COX-2 in nasopharyngeal carcinoma patients (P< 
0.05). Table 3 showed the association of MMP-9 and COX-2 overexpression 
in NPC patients. It showed that majority of NPC patients in this study had 
both MMP-9 and COX-2 overexpression which were 70 NPC patients. In 
addition, Chi-square test was result in significant association of MMP-9 
overexpression with COX-2 overexpression with P<0.05. 
4. DISCUSSION 
Overexpression of MMP-9 was found in the nasopharyngeal carcinoma 
patients. MMP-9 is an enzyme as the part of matrix metalloproteinases 
group, zinc dependent proteins. MMP-9 has role in physiologic and 
pathologic process. It is found most in cells in inflammation and neoplasia 
condition. MMP-9 could be induced by several factors including cytokines, 
lipopolysaccharide, TNF-α, extracellular matrix components, and growth 
factor. MMP-9 has role in the degradation of extracellular matrix (ECM) 
components and also has the ability in affecting activities of cytokines and 
chemokines, growth factors, and proteinase inhibitors [17, 18].  
However, MMP-9 is also involved in tumorigenesis and metastasis of 
tumor cells through tumor growth regulation, angiogenesis, migration of 
cells, and invasion. It degrades gelatin and type IV, V, XI, and XVI 
collagen which responsible for the invasion and metastasis of cells [18]. 
The mechanism of MMP-9 in degradation of collagen was thought as it 
has fibronectin repeats that allow it to recognize the gelatin as substrate. 
There are invadopodia, an actin rich invasive protrusions common found 
in cancer cells. It has the ability to degrade extracellular matrix by the 
presence of MMP-9. It was thought that invadopdia release MMP-9 to 
facilitate invasion [19].  







High expression of MMP-9 has been associated with poor prognosis in 
various tumors [18]. Study by Liu et al. showed high expression of MMP-9 
in nasopharyngeal carcinoma at the proportion 77.4% (127/164) of samples. 
The study also correlated the association of MMP-9 overexpression with 
clinicopathological characteristic of nasopharyngeal carcinoma patients. 
Overexpression of MMP-9 was correlate with lymph node status (N0-N1 vs 
N2-N3) and clinical staging (I-II vs III-IV) of nasopharyngeal carcinoma 
patients. In addition, it also showed that nasopharyngeal carcinoma patients 
with high expression of MMP-9 had poorer prognosis and adjusted MMP-9 
as independent prognostic marker for nasopharyngeal carcinoma [20]. 
This study also supported by study from Cheng et al. which showed the 
high serum level of MMP-9 in nasopharyngeal carcinoma patients and the 
significant association with N classification and clinical staging (P< 
0.001).The shorter overall survival of nasopharyngeal carcinoma patients 
with high expression of MMP-9 was found in that study, as well as MMP-9 
as the independent prognostic factor [8]. Study by Li et al. also showed the 
high expreesion of MMP-9 in nasopharyngeal carcinoma patients [21]. 
Other studies also revealed the overexpression of MMP-9 and the 
association with clinicopathological characteristic and prognosis in several 
cancer including gastric cancer, oral squamous cell carcinoma, and breast 
cancer [18, 22-24]. 
This study revealed the overexpression of COX-2 in nasopharyngeal 
carcinoma patients. COX-2 is a part of cyclooxygenase which is enzyme 
involving in prostaglandin production. Its other name is prostaglandin-
endoperoxide synthase 2 and most commonly found during inflammation 
and in various human cancers [10, 25]. COX-2 can be induced by mitogenic 
and inflammatory stimuli as well as Latent Membrane Protein–1 (LMP1), a 
protein produced by EBV latent infection [9]. COX-2 activity result in 
prostaglandin E2 (PGE2) production which induce carcinogenesis through 
modulate xenobiotic metabolism, cell protection against apoptosis, 
potentiation for cell proliferation, angiogenesis, invasiveness, and 
metastasis.[10, 25]. COX-2 induced by LMP1 is along with induce of 
Vascular Endothelial Growth Factor (VEGF), support its role in enhancing 
angiogenesis of cancer tissue [26, 27]. 
Several studies showed the overexpression of COX-2 in 
nasopharyngeal carcinoma patients. Study by Pan et al. showed the 
overexpression of COX-2 in 76.6% of nasopharyngeal carcinoma biopsies 
and associated with poor overall survival rate [11]. Tan et al. in their study 
revealed COX-2 overexpression in 60 of 78 nasopharyngeal carcinoma 
patients. The study also result in no association of COX-2 overexpression 
with the tumor stage [25]. Study by Shi et al, showed the overexpression of 
COX-2 in 200 nasopharyngeal carcinoma patients. It also showed the 
association of clinical stage, T and N classification, distant metastasis, and 
recurrence of the disease with COX-2 overexpression. Patients with 
overexpression of COX-2 was found had shorter survival than low 
expression of COX-2 [28]. 
The studies also supported by A. Fendri et al. in their study which 
showed the positive expression of COX-2 in 41 of 45 (91%) patients. 
There was significant correlation between COX-2 overexpression with 
nasopharyngeal carcinoma. They also found that there was association 
of lymph node involvement with COX-2 overexpression. Stage N+was 
more common for the occurrence of COX-2 expression in 95.23% 
proportion of samples [26]. Study by Xinhua et al. found the expression 
of COX-2 in 63 of 86 (73.3%) nasopharyngeal carcinoma patients. 
Patients with high expression of COX-2 had shorter survival period than 
low COX-2 expression [27].  
Study by Saba et al. showed the expression of COX-2 in head and neck 
squamous cell carcinoma. The study showed COX-2 expression in 38 of 54 
patients with invasive head and neck squamous cell carcinoma. It also found 
the correlation of primary tumor T stage with the expression of COX-2. 
According to 5-year overall survival rate, patients with higher COX-2 
expression had smaller rate than lower COX-2 expression. It showed the 
significant of COX-2 as the survival predictor by means as prognostic factor 
[29] However, meta-analysis study by Yang et al, result in no significant 
association of COX-2 expression in head and neck cancer, including oral 
cancer, laryngeal cancer, nasopharyngeal carcinoma, and no site specific 
head and neck cancer group. There were association of COX-2 
overexpression and lymph node metastasis in oral cancer, but not in other 
cancers. COX-2 overexpression were significantly associate with TNM 
stage in oral cancer and no site specific head and neck cancer group, but not 
significant in laryngeal cancer and nasopharyngeal cancer [30]. Majority of 
the studies focus on prognostic value of COX-2 and the benefit of COX-2 
inhibitor in cancer. COX-2 inhibitor in the treatment for cancer mainly 
associate with other factors such as MMPs and tumor necrosis factor – α 
(TNF-α) [12, 17]. 
 Relation of MMP-9 and COX-2 are remain unclear. Upregulation of 
MMP-9 was thought induced by expression of COX-2 and PGE2 as the 
result of macrophage exposure to MMP-1 and MMP-3. Experimental study 
by Li et al. showed the effectiveness of celecoxib, a COX-2 inhibitor in 
downregulation of MMP-9 in nasopharyngeal carcinoma cell in vitro, 
supported the assumption for COX-2 involvement in the expression of 
MMP-9. It was supported by experimental study by Bu et al. in their study 
that found significant decrease of MMP-9 expression after celecoxib given 
in pancreatic carcinoma cells and experimental study by Steenport et al. in 
normal tissue of mice which result in similar form [12, 17]. Our study 
showed the overexpression of both MMP-9 and COX-2 in 70/98 
nasopharyngeal carcinoma patients with significant association with the 
primary tumor size, lymph node enlargement, and clinical staging. We also 
found the association between MMP-9 with COX-2 in nasopharyngeal 
carcinoma patients. We suggested the expression of COX-2 increase MMP-
9 expression lead to increase stage of the disease due to MMP’s role in 
affecting invasion and metastasis of cancer cells. 
5. CONCLUSION 
The study of 98 samples revealed the overexpression of MMP-9, COX-
2, and the combination of those two in nasopharyngeal carcinoma patients. 
There were significant association of the overexpression with primary tumor 
size, lymph node enlargement, the presence of distant metastasis, and 
clinical staging. There was association between MMP-9 with COX-2 
overexpression. Further research was needed to identify clear association 
between MMP-9 and COX-2 in nasopharyngeal carcinoma patients. 
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